The cause of death was ovarian cancer, her family said.

"Has anyone in your family on either side ever had ovarian cancer?"

Have a family history of ovarian cancer before age 50.

You have a strong family history of early ovarian cancer.

You will continue to have a high risk for ovarian cancer.

No cases of ovarian cancer have been reported in these studies.

The end of ovarian cancer is not a bit like that.

My mom died of ovarian cancer when I was only five.

It may also be done to lower the risk of ovarian cancer.

Women are more likely to get ovarian cancer if others in their family have had it.

But getting medical care right away may help find ovarian cancer at an early stage.

A woman has a better chance of successful treatment when ovarian cancer is found early.

There is no first name for the mother, a French teacher who died from ovarian cancer two years ago.

The average age for developing ovarian cancer is 61 years old.

See a picture that may help you understand how much having a family history can increase your risk for ovarian cancer.

But for ovarian cancer scientists are still coming up short.

In fact, the more children a woman has had, the less likely she is to develop ovarian cancer.

A friend said that she had Stage 4 ovarian cancer.

And, most women with ovarian cancer do not have any strong risk factors for the disease.

But they have found that certain factors make ovarian cancer less likely.

When you've got ovarian cancer, you may not feel like eating much.

These drugs may be even more effective than the current ovarian cancer treatment.

In 2013, after several months of treatment, Brown once again won her battle with ovarian cancer.

"This may be particularly important for women with an increased risk of ovarian cancer in their family."

Your doctor is concerned that ovarian cancer may be present.

The vast majority of ovarian cancers are epithelial ovarian carcinomas.

The pathogenesis of ovarian carcinoma remains unclear.

Ovarian carcinoma and some types of brain tumor are debulked prior to commencing radio- or chemotherapy.

Supporting this is the observation that in ovarian carcinomas, loss of c-Fos expression correlates with disease progression.

Ovarian carcinomas are common.

CA 125 is a tumor-associated antigen that is used clinically to monitor patients with epithelial ovarian carcinomas.

A study to evaluate the association between germline genetic variation and disease risk and outcome in ovarian carcinoma in Pakistan.

Metastatic tumour, e.g. ovarian carcinoma.

HeLa cervical cancer cells and SKOV3 ovarian carcinoma were experimented upon.

LM and SEM aspects of autoschizic cell death of ovarian carcinoma cells.

This includes multiple human tumor cell lines including glioblastoma, melanoma, ovarian carcinoma, prostatic carcinoma, and breast carcinomas).

Progesterone has been found [ 46] to inhibit cell proliferation and induce apoptosis significantly in two ovarian carcinoma cell lines.

Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids: a prospective analysis.

Gain of EMT markers was found to be associated with the resistance of ovarian carcinoma epithelial cell lines to paclitaxel.

The present data suggest that diminished levels of BRCA1 not only accelerate proliferation in the BG-1 ovarian carcinoma cell line, but appear to alter tumorigenesis.

It can be used for treating some types of non-Hodgkin lymphoma, Waldenström macroglobulinemia, polycythemia vera, trophoblastic neoplasms, and ovarian carcinoma.

Often AGID is a symptom of other problems including colon cancer, lupus, lung, breast, or ovarian carcinoma or thymoma.

In ovarian cancers, 75% of low malignancy tumors and 65% of invasive ovarian carcinomas are H19 RNA positive.

Barnhill D, Heller P, Brzozowski P, et al.: Epithelial ovarian carcinoma of low malignant potential.

Girls with ovarian carcinoma (epithelial ovarian neoplasia) fare better than adults with similar histology, probably because girls usually present with low-stage disease.

A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity.

"It is used to treat a wide variety of solid tumors but is best known for its effectiveness on ovarian carcinoma, a tumor that is very difficult to treat."

Levin L, Simon R, Hryniuk W: Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.

Lynch HT, Bewtra C, Lynch JF: Familial ovarian carcinoma.

Thigpen T, Brady MF, Omura GA, et al.: Age as a prognostic factor in ovarian carcinoma.